Literature DB >> 27757796

Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.

Yugang Cheng1, Hanxiang Zhan1, Lei Wang1, Jianwei Xu1, Guangyong Zhang1, Zongli Zhang2, Sanyuan Hu3.   

Abstract

The incidence rate of pancreatic neuroendocrine neoplasms (pNENs) has increased rapidly in recent years. However, the clinicopathological characteristics of pNENs are poorly understood. Medical records of patients who underwent surgery and were confirmed as pNENs by pathological examination from January 2003 to February 2015 in Qilu Hospital were reviewed retrospectively. A total of 100 patients, 36 males and 64 females, were included with a mean operation age of 46.26 + 13.41 years. Among the 100 cases, 76 had insulinomas and 24 had non-functional pNENs. Tumor size ranged from 0.5 cm to 9 cm, and the mean size was 2.20 + 1.40 cm. The percentages of TNM stages I, II, III, and IV tumors were 89.0%, 8.0%, 0.0%, and 3.0%, respectively. Based on the WHO classification, pNENs were classified into three grades: G1, G2, and G3. G1, G2, and G3 tumors were confirmed in 72.9%, 23.7%, and 3.4% patients, respectively. The positive rates of CgA and Syn immunohistochemical staining were 94.5% (69/73) and 100% (74/74), respectively. Compared with insulinoma, non-functional pNENs have larger tumor sizes, more advanced TNM staging, a higher Ki-67 index, and a higher rate of liver metastasis (P < 0.05). In conclusion, pNENs are heterogeneous tumors with varying clinical manifestations, diverse tumor biological characteristics, and different prognoses. Non-functional pNENs present a more aggressive behavioral model and have poorer prognosis than functional pNENs.

Entities:  

Keywords:  Ki-67; clinicopathological characteristic; liver metastasis; outcomes; pancreatic neuroendocrine neoplasms

Mesh:

Substances:

Year:  2016        PMID: 27757796     DOI: 10.1007/s11684-016-0471-x

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  25 in total

1.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.

Authors:  Massimo Falconi; Detlef Klaus Bartsch; Barbro Eriksson; Günter Klöppel; José M Lopes; Juan M O'Connor; Ramón Salazar; Babs G Taal; Marie Pierre Vullierme; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Asima Cheema; Jill Weber; Gang Han; Domenico Coppola; Larry K Kvols
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Surgical management of patients with insulinomas: Result of 292 cases in a single institution.

Authors:  Yu-Pei Zhao; Han-Xiang Zhan; Tai-Ping Zhang; Lin Cong; Meng-Hua Dai; Quan Liao; Li-Xing Cai
Journal:  J Surg Oncol       Date:  2010-12-22       Impact factor: 3.454

4.  TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.

Authors:  G Rindi; M Falconi; C Klersy; L Albarello; L Boninsegna; M W Buchler; C Capella; M Caplin; A Couvelard; C Doglioni; G Delle Fave; L Fischer; G Fusai; W W de Herder; H Jann; P Komminoth; R R de Krijger; S La Rosa; T V Luong; U Pape; A Perren; P Ruszniewski; A Scarpa; A Schmitt; E Solcia; B Wiedenmann
Journal:  J Natl Cancer Inst       Date:  2012-04-23       Impact factor: 13.506

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 6.  A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours.

Authors:  Juan W Valle; Martin Eatock; Ben Clueit; Zahava Gabriel; Roxanne Ferdinand; Stephen Mitchell
Journal:  Cancer Treat Rev       Date:  2013-09-08       Impact factor: 12.111

7.  Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.

Authors:  L Fischer; J Kleeff; I Esposito; U Hinz; A Zimmermann; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

Review 8.  Current understanding of the molecular biology of pancreatic neuroendocrine tumors.

Authors:  Jianliang Zhang; Rony Francois; Renuka Iyer; Mukund Seshadri; Maria Zajac-Kaye; Steven N Hochwald
Journal:  J Natl Cancer Inst       Date:  2013-07-09       Impact factor: 13.506

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.

Authors:  Yu-hong Wang; Qiu-chen Yang; Yuan Lin; Ling Xue; Min-hu Chen; Jie Chen
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

View more
  2 in total

1.  A New Preoperative Scoring System for Predicting Aggressiveness of Non-Functioning Pancreatic Neuroendocrine Neoplasms.

Authors:  Tetsuya Takikawa; Kazuhiro Kikuta; Shin Hamada; Kiyoshi Kume; Shin Miura; Naoki Yoshida; Yu Tanaka; Ryotaro Matsumoto; Mio Ikeda; Fumiya Kataoka; Akira Sasaki; Hidehiro Hayashi; Waku Hatta; Yohei Ogata; Kei Nakagawa; Michiaki Unno; Atsushi Masamune
Journal:  Diagnostics (Basel)       Date:  2022-02-03

2.  A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.

Authors:  Yong Gao; Hao Gao; Guangfu Wang; Lingdi Yin; Wenbin Xu; Yunpeng Peng; Junli Wu; Kuirong Jiang; Yi Miao
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.